Author: WallStreetReview

Tilray’s stock surges after Benchmark starts coverage with bullish rating, $200 target

WallStreetReview
Tilray’s stock surges after Benchmark starts coverage with bullish rating, $200 target
Shares of Tilray Inc. TLRY, +11.69% shot up 5.7% in premarket trade Tuesday, after Benchmark analyst Mike Hickey started coverage of the Canada-based medical cannabis and cannabinoid company with a buy rating and $200 price target. Hickey’s price target is 21% above Monday’s closing price $165.64. Hickey said his bullish view is based on the company’s early leadership in the... Read More

Morgan Stanley’s stock jumps after profit, revenue rise above expectations

WallStreetReview
Morgan Stanley’s stock jumps after profit, revenue rise above expectations
Shares of Morgan Stanley rallied 1.9% in premarket trade Tuesday, after the investment bank reported third-quarter profits and revenue that rose above expectations. Net income rose to $2.02 billion, or $1.17 a share, from $1.69 billion, or 93 cents a share, in the same period a year ago. The FactSet consensus for earnings per share was $1.01. Total revenue increased... Read More

Wells Fargo seeks investment firm licence from French regulator as part of Brexit strategy

WallStreetReview
Wells Fargo seeks investment firm licence from French regulator as part of Brexit strategy
Wells Fargo & Co. WFC, +2.17% said Tuesday it is seeking an investment firm licence from the French regulator as part of its Brexit strategy. “With Brexit on the horizon, Wells Fargo is committed to providing a transition, which is as seamless as possible, for its markets and investment banking customers within the European Union (EU) and European Economic Area... Read More

Do You Have These Pharma Stocks In Your Portfolio? (EARS, BLRX, OMED…)

WallStreetReview
Do You Have These Pharma Stocks In Your Portfolio? (EARS, BLRX, OMED…)
Clinical trials are major catalysts for biotech/pharma companies as positive study data can boost the stock price while unfavorable results can send the stocks plummeting. The success rate of phase I clinical programs is the highest, say 63%, while it is the lowest for phase II trials – i.e. 30%. The phase III trials, which are the longest and most... Read More

European Shares Mixed In Cautious Trade

WallStreetReview
European Shares Mixed In Cautious Trade
European stocks bounced back from 22-monht lows on Tuesday, although U.K. markets were trading lower as the British pound extended gains after the release of labor market data showing that U.K. wages grew faster than expected in August. The Average Earnings Index, with bonuses included, stood at 2.7 percent in the month, up from 2.6 percent in the previous month... Read More